Combination treatment for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug combination for a type of lung cancer called squamous non-small cell lung cancer. It aims to see if the combination can help people whose cancer has grown after standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have squamous non-small cell lung cancer that has progressed after treatment with immunotherapy and chemotherapy.
- Your tumor tests positive for a protein called EGFR (you can ask your doctor to check).
- You have not been treated with EGFR inhibitors or docetaxel before.
- You are generally well enough to carry out daily activities (ECOG score 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination treatment (SCTB41 plus docetaxel) for people with advanced non-small cell lung cancer who have already tried other treatments. The goal is to see if this combination can help shrink or control the cancer.
This study tests a new drug called JSKN016 in people with advanced non-small cell lung cancer whose standard treatments have stopped working. The drug may help shrink tumors or slow the cancer's growth, and the study looks at safety and effectiveness.
This study tests a new combination of drugs (SYHX2011, carboplatin, and an immunotherapy called enlonstobart) as the first treatment for advanced squamous lung cancer that is PD-L1 positive. The goal is to see if this combination helps shrink tumors and slow cancer growth.
This trial tests a new drug combination for people with advanced non-small cell lung cancer (NSCLC) that cannot be removed with surgery or cured with radiation. It aims to see if the combination is safe and effective.
This trial tests a new drug (JS207) that targets both PD-1 and VEGF pathways, given alone or with other treatments, for people with advanced non-small cell lung cancer that has a specific gene change and has stopped responding to targeted therapy (TKI). The goal is to see if this combination can help shrink tumors or slow cancer growth.
This trial tests a new drug (SCTB41) combined with chemotherapy for people with advanced squamous non-small cell lung cancer who have not had any prior treatment. It aims to see if this combination works better than standard therapy.
Hear when a new Squamous Cell Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.